Medicaid expansion can raise demand for gynecologic cancer care
An expansion of Medicaid services in the state of Virginia led within months to more young and middle-aged women of lower income being treated in…
Steve Bryson, PhD, science writer — 
Articles by Steve Bryson
New atlas details immune cell changes as disease progresses
Researchers in Belgium have developed an atlas to mark changes in distinct types of immune cells during multiple myeloma’s  progression. Their work, in…
FDA approves Imkeldi, imatinib as oral liquid, for certain leukemias
The U.S. Food and Drug Administration (FDA) has approved an oral liquid formulation of imatinib, now called Imkeldi, to treat specific forms of…
FDA approves revumenib for select acute leukemias with KMT2A defect
The U.S. Food and Drug Administration (FDA) has approved revumenib, now called Revuforj, as an oral therapy for children and adults, ages 1 year and…
Treatment before surgery slows PDAC disease progression: Study
Neoadjuvant therapy, or treatment to shrink tumors before the surgery to remove them, delayed disease progression, reduced recurrence, and extended survival in people with pancreatic…
Ovarian cancer lessens efficacy of T-cell immunotherapy, study finds
The microenvironment of ovarian cancer tumors actively suppress the work of immune T-cells by blocking their energy supply, a study reports. These findings have implications…
Stem cell transplant is safe, effective in myeloma: Global real-world study
A standard autologous hematopoietic stem cell transplant (AHSCT) safely and effectively prolongs survival and delays cancer progression in adults with multiple myeloma, a…
FDA grants Poseida’s CAR T-cell therapy RMAT status for RRMM
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) status to P-BCMA-ALLO1, Poseida Therapeutics‘ experimental CAR T-cell therapy for…
Blood test may predict patients’ responses to CAR T-cell therapy
A blood test measuring numbers of lymphocytes, a type of immune cell, may predict how well people with relapsed multiple myeloma will respond to…
CAR T-cell therapy Carvykti OK’d as second-line RRMM treatment
The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) as a second line of treatment for adults…